Molecular Templates (NASDAQ:MTEM) Shares Cross Above Two Hundred Day Moving Average of $7.19

Molecular Templates, Inc. (NASDAQ:MTEMGet Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $7.19 and traded as high as $8.17. Molecular Templates shares last traded at $7.99, with a volume of 8,873 shares changing hands.

Molecular Templates Price Performance

The firm has a market capitalization of $42.96 million, a price-to-earnings ratio of -0.64 and a beta of 1.40. The stock has a fifty day moving average of $8.29 and a two-hundred day moving average of $7.19.

Molecular Templates (NASDAQ:MTEMGet Free Report) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($3.30) EPS for the quarter, beating analysts’ consensus estimates of ($5.25) by $1.95. The business had revenue of $6.87 million for the quarter. Molecular Templates had a negative net margin of 92.78% and a negative return on equity of 1,843.37%. On average, research analysts forecast that Molecular Templates, Inc. will post -6.15 EPS for the current year.

Insider Buying and Selling at Molecular Templates

In related news, major shareholder Target N. V. Biotech acquired 283,687 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were bought at an average price of $7.05 per share, with a total value of $1,999,993.35. Following the transaction, the insider now directly owns 1,029,821 shares of the company’s stock, valued at $7,260,238.05. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 18.70% of the company’s stock.

Institutional Investors Weigh In On Molecular Templates

Several large investors have recently modified their holdings of the stock. Carlyle Group Inc. purchased a new stake in shares of Molecular Templates during the 1st quarter worth approximately $75,000. Millennium Management LLC increased its stake in shares of Molecular Templates by 26.3% during the 4th quarter. Millennium Management LLC now owns 308,061 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 64,156 shares during the last quarter. Credit Suisse AG purchased a new stake in shares of Molecular Templates during the 4th quarter worth approximately $336,000. Goldman Sachs Group Inc. increased its stake in shares of Molecular Templates by 39.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 169,087 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 47,839 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new stake in shares of Molecular Templates during the 2nd quarter worth approximately $29,000.

About Molecular Templates

(Get Free Report)

Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform.

Featured Articles

Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.